Efficacy and safety of 2 doses of agomelatine (10 mg/day or 25 mg/day) versus placebo in generalized anxiety disorder

被引：0
|
作者：
Stein, D. [1 ,2 ]
Ahokas, A. [3 ]
Jarema, M. [4 ]
Avedisova, A. S. [5 ]
Vavrusova, L. [6 ]
Chaban, O. [7 ]
Olivier, V. [8 ]
Gruget, C. [8 ]
Picarel-Blanchot, F. [8 ]
De Bodinat, C. [8 ]
机构：
[1] Univ Cape Town, Cape Town, South Africa
[2] Mt Sinai Sch Med, Dept Psychiat, Cape Town, South Africa
[3] Mehilainen Clin, Dept Psychiat, Helsinki, Finland
[4] Ctr Terapii Dialog, Warsaw, Poland
[5] Psychiat Hosp 12, Moscow, Russia
[6] Univ Hosp Bratislava, Dept Psychiat, Bratislava, Slovakia
[7] Railway Clin Hosp, Psychoneurol Dept, Kiev, Ukraine
[8] Inst Rech Int Servier, Pole Innovat Therapeut Neuropsychiat, Suresnes, France
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2016年 / 26卷
关键词：
D O I：
10.1016/S0924-977X(16)31678-9
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.4.b.003
引用
收藏
页码：S601 / S602
页数：2
相关论文
共 50 条
  • [1] Efficacy and safety of agomelatine 25-50 mg/day versus escitalopram 10-20 mg/day in severe generalized anxiety disorder
    Stein, D. J.
    Khoo, J. P.
    Van Ameringen, D. M.
    Hoschl, C.
    Ahokas, A.
    Bauer, M.
    Bitter, I.
    Jarema, M.
    Mosolov, S.
    Vavrusova, L.
    Picarel-Blanchot, F.
    Matharan, S.
    Olivier, V.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 : S1003 - S1003
  • [2] EFFICACY AND SAFETY OF AGOMELATINE (25-50 MG/DAY) VERSUS ESCITALOPRAM (10-20 MG/DAY) IN SEVERE GENERALIZED ANXIETY DISORDER
    Stein, D.
    Khoo, J-P
    Van Ameringen, M.
    Hoschl, C.
    Ahokas, A.
    Bauer, M.
    Bitter, I.
    Jarema, M.
    Mosolov, S. N.
    Vavrusova, L.
    Picarel-Blanchot, F.
    Olivier, V.
    de Bodinat, C.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2018, 52 : 136 - 137
  • [3] Efficacy and safety of agomelatine 25-50 mg/day versus escitalopram 10-20 mg/day in severe generalised anxiety disorder
    Khoo, J. -P.
    Stein, D.
    Ameringen, M. V.
    Hoschl, C.
    Ahokas, A.
    Bauer, M.
    Bitter, I.
    Jarema, M.
    Mosolov, S. N.
    Vavrusova, L.
    Picarel-Blanchot, F.
    Olivier, V.
    deBodinat, C.
    BIPOLAR DISORDERS, 2019, 21 : 135 - 135
  • [4] Efficacy and safety of agomelatine 25-50 mg/day versus venlafaxine XR 75-150-225 mg/day in non-depressed asian outpatients with generalized anxiety disorder
    Picarel, F.
    Zhao, J. P.
    Sulaiman, A. H.
    Huang, Y. S.
    Srisurapanont, M.
    Wei, K. C.
    Severo, C. Albarran
    Olivier, V.
    de Bodinat, C.
    EUROPEAN PSYCHIATRY, 2018, 48 : S145 - S146
  • [5] 12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25-50 mg/day) versus escitalopram (10-20 mg/day) in out-patients with severe generalized anxiety disorder
    Stein, Dan J.
    Khoo, Jon-Paul
    Ahokas, Antti
    Jarema, Marek
    Van Ameringen, Michael
    Vavrusova, Livia
    Hoschl, Cyril
    Bauer, Michael
    Bitter, Istvan
    Mosolov, Sergey N.
    Olivier, Valerie
    Matharan, Sophie
    Picarel-Blanchot, Francoise
    de Bodinat, Christian
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2018, 28 (08) : 970 - 979
  • [6] lEfficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: A 12-week, double-blind, placebo-controlled study
    Stein, Dan J.
    Ahokas, Antti
    Jarema, Marek
    Avedisova, Alla S.
    Vavrusova, Livia
    Chaban, Oleg
    Gruget, Celine
    Olivier, Valerie
    Picarel-Blanchot, Francoise
    de Bodinat, Christian
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 (05) : 526 - 537
  • [7] The efficacy and safety of ziprasidone 80 mg/day and 160 mg/day in schizophrenia and schizoaffective disorder
    Daniel, D
    Reeves, K
    Harrigan, EP
    SCHIZOPHRENIA RESEARCH, 1997, 24 (1-2) : 204 - 204
  • [8] Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder
    Liebowitz, Michael R.
    Manley, Amy L.
    Padmanabhan, Sudharshan K.
    Ganguly, Rita
    Tummala, Raj
    Tourian, Karen A.
    CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (07) : 1877 - 1890
  • [9] The efficacy and safety of 10 mg/day vortioxetine compared to placebo for adult major depressive disorder: a meta-analysis
    Zheng, Jiahuan
    Wang, Zhaoyu
    Li, Enli
    AFRICAN HEALTH SCIENCES, 2019, 19 (01) : 1716 - 1726
  • [10] A placebo-controlled study of three agomelatine dose regimens (10 mg, 25 mg, 25-50 mg) in patients with major depressive disorder
    Kennedy, Sidney H.
    Avedisova, Alla
    Gimenez-Montesinos, Natalia
    Belaidi, Carole
    de Bodinat, Christian
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 (04) : 553 - 563
12345